Results 1 to 10 of about 16,268 (199)

Aztreonam-avibactam may not replace ceftazidime/avibactam: the case of KPC-21 carbapenemase and penicillin-binding protein 3 with four extra amino acids

International Journal of Antimicrobial Agents, 2022
Zhiyong Zong, Yu Feng
exaly  

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Antimicrobial Agents and Chemotherapy, 2017
Ryan K Shields, Liang Chen, Shaoji Cheng   +2 more
exaly  

Avibactam Pharmacokinetic/Pharmacodynamic Targets

Antimicrobial Agents and Chemotherapy, 2018
Wright W Nichols, Paul Newell, Ian A Critchley   +2 more
exaly  

Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China

Clinical Microbiology and Infection, 2020
Xueqing Wu, Murat áková
exaly  

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

Antimicrobial Agents and Chemotherapy, 2017
Ryan K Shields, M Hong Nguyen, Liang Chen   +2 more
exaly  

Randomized pharmacokinetic and drug–drug interaction studies of ceftazidime, avibactam, and metronidazole in healthy subjects

Pharmacology Research and Perspectives, 2015
Shampa Das, Jon Armstrong
exaly  

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Clinical Infectious Diseases, 2016
Ryan K Shields, Brian A Potoski, Ghady Haidar   +2 more
exaly  

Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota

International Journal of Antimicrobial Agents, 2015
Mamun-Ur Rashid, Staffan Rosenborg, Georgios Panagiotidis   +2 more
exaly  

Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo

Journal of Antimicrobial Chemotherapy, 2019
Stephan Göttig, Denia Frank, Silke Besier   +2 more
exaly  

In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae

International Journal of Antimicrobial Agents, 2012
Oral Oncul, Zerrin Aktas
exaly